Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 203.3% in December

Posted by Lauren Steadman on Jan 16th, 2025

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 18,500 shares, an increase of 203.3% from the December 15th total of 6,100 shares. Based on an average daily volume of 10,700 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.

Get Our Latest Analysis on ARMP

Armata Pharmaceuticals Trading Down 1.0 %

Shares of ARMP traded down $0.02 during trading hours on Wednesday, hitting $2.00. The company had a trading volume of 3,833 shares, compared to its average volume of 12,837. The firm has a market cap of $72.36 million, a price-to-earnings ratio of -1.22 and a beta of 0.78. Armata Pharmaceuticals has a one year low of $1.80 and a one year high of $4.48.

About Armata Pharmaceuticals

(Get Free Report)

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.